Waldencast Obagi shares interim ALOHA trial data for Saypha MagIQ dermal filler

• Waldencast unit Obagi Medical presented new clinical and real-world data at Music City SCALE meeting running May 13-17 in Nashville.
• 12-week open-label study of NU-GEN Cellular Renewal Serum showed visible improvements across multiple signs of skin aging, supporting positioning of product as anti-aging regimen without disclosing detailed measurements.
• Interim readout from ALOHA real-world program for Obagi Saypha MagIQ hyaluronic acid filler indicated broad injector acceptance as complement to existing filler portfolios, supporting commercial rollout strategy in aesthetic practices.
• Program data also signaled cross-selling potential, with meaningful share of filler patients evaluating Obagi skincare alongside injectables.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150813PRIMZONEFULLFEED9720674) on May 15, 2026, and is solely responsible for the information contained therein.